Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. [electronic resource]
Producer: 20170809Description: 147-155 p. digitalISSN:- 1097-6744
- Adenosine Monophosphate -- administration & dosage
- Administration, Oral
- Aged
- Cause of Death -- trends
- Clopidogrel
- Coronary Angiography
- Coronary Artery Disease -- diagnosis
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Follow-Up Studies
- Global Health
- Humans
- Incidence
- Infusions, Intravenous
- Male
- Middle Aged
- Myocardial Infarction -- epidemiology
- Percutaneous Coronary Intervention
- Postoperative Complications -- epidemiology
- Purinergic P2Y Receptor Antagonists -- administration & dosage
- Survival Rate -- trends
- Ticlopidine -- administration & dosage
- Time Factors
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.